Remyelination in multiple sclerosis: Cellular mechanisms and novel therapeutic approaches

Journal of Neuroscience Research

Volumn 93, Issue 5, 2015, Pages 687-696

  Olsen, John A ^a   Akirav, Eitan M ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Demyelination; Multiple sclerosis; Myelination; Oligodendrocytes; Remyelination

Indexed keywords

BENZATROPINE; BETA INTERFERON; BIIB 033; CUPRIZONE; FINGOLIMOD; IMMUNOGLOBULIN G1 ANTIBODY; MYELIN; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL MIGRATION; CELL THERAPY; CENTRAL NERVOUS SYSTEM; DEMYELINATION; HUMAN; IN VIVO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE FIBER; NEURAL STEM CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REMYELINIZATION; REVIEW; ANIMAL; NERVE REGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE REGENERATION; OLIGODENDROGLIA;

EID: 84925637763     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23493     Document Type: Review

References (113)

1. Akirav EM, Xu Y, Ruddle NH. 2011. Resident B cells regulate thymic expression of myelin oligodendrocyte glycoprotein. J Neuroimmunol 235:33-39.
2. Armstrong RC, Dorn HH, Kufta CV, Friedman E, Dubois-Dalcq ME. 1992. Preoligodendrocytes from adult human CNS. J Neurosci 12:1538-1547.
3. Arnett HA, Wang Y, Matsushima GK, Suzuki K, Ting JP. 2003. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 23:9824-9832.
4. Barres BA, Raff MC. 1999. Axonal control of oligodendrocyte development. J Cell Biol 147:1123-1128.
5. Barres BA, Jacobson MD, Schmid R, Sendtner M, Raff MC. 1993. Does oligodendrocyte survival depend on axons? Curr Biol 3:489-497.
6. Berg GJ, Schachner M. 1982. Electron-microscopic localization of A2B5 cell surface antigen in monolayer cultures of murine cerebellum and retina. Cell Tissue Res 224:637-645.
7. Bitsch A, Bruck W. 2002. Differentiation of multiple sclerosis subtypes: implications for treatment. CNS Drugs 16:405-418.
8. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. 2000. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123:1174-1183.
9. Boven LA, Van Meurs M, Van Zwam M, Wierenga-Wolf A, Hintzen RQ, Boot RG, Aerts JM, Amor S, Nieuwenhuis EE, Laman JD. 2006. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129:517-526.
10. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, Laursen H. 2010. Demyelination versus remyelination in progressive multiple sclerosis. Brain 133:2983-2998.
11. Brockschnieder D, Lappe-Siefke C, Goebbels S, Boesl MR, Nave KA, Riethmacher D. 2004. Cell depletion due to diphtheria toxin fragment A after Cre-mediated recombination. Mol Cell Biol 24:7636-7642.
12. Buch T, Heppner FL, Tertilt C, Heinen TJ, Kremer M, Wunderlich FT, Jung S, Waisman A. 2005. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods 2:419-426.
13. Bunge MB, Bunge RP, Pappas GD. 1962. Electron microscopic demonstration of connections between glia and myelin sheaths in the developing mammalian central nervous system. J Cell Biol 12:448-453.
14. Carnegie PR. 1971. Amino acid sequence of the encephalitogenic basic protein from human myelin. Biochem J 123:57-67.
15. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. 2000. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 20:6404-6412.
16. Chang A, Tourtellotte WW, Rudick R, Trapp BD. 2002. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346:165-173.
17. Chang A, Staugaitis SM, Dutta R, Batt CE, Easley KE, Chomyk AM, Yong VW, Fox RJ, Kidd GJ, Trapp BD. 2012. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol 72:918-926.
18. Colman DR, Kreibich G, Frey AB, Sabatini DD. 1982. Synthesis and incorporation of myelin polypeptides into CNS myelin. J Cell Biol 95:598-608.
19. Coman I, Aigrot MS, Seilhean D, Reynolds R, Girault JA, Zalc B, Lubetzki C. 2006. Nodal, paranodal, and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain 129:3186-3195.
20. Constantinescu CS, Farooqi N, O'Brien K, Gran B. 2011. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164:1079-1106.
21. Cramer SP, Simonsen H, Frederiksen JL, Rostrup E, Larsson HB. 2013. Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. Neuroimage Clin 4:182-189.
22. Damasceno A, Damasceno BP, Cendes F. 2014. The clinical impact of cerebellar grey matter pathology in multiple sclerosis. PLoS One 9:e96193.
23. Dasgupta S, Jana M, Liu X, Pahan K. 2002. Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis. J Biol Chem 277:39327-39333.
24. de Castro F, Bribian A. 2005. The molecular orchestra of the migration of oligodendrocyte precursors during development. Brain Res Brain Res Rev 49:227-241.
25. Deshmukh VA, Tardif V, Lyssiotis CA, Green CC, Kerman B, Kim HJ, Padmanabhan K, Swoboda JG, Ahmad I, Kondo T, Gage FH, Theofilopoulos AN, Lawson BR, Schultz PG, Lairson LL. 2013. A regenerative approach to the treatment of multiple sclerosis. Nature 502:327-332.
26. + glial precursor cells from cryopreserved human fetal brain progenitor cells. Glia 40:65-77.
27. di Penta A, Moreno B, Reix S, Fernandez-Diez B, Villanueva M, Errea O, Escala N, Vandenbroeck K, Comella JX, Villoslada P. 2013. Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One 8:e54722.
28. Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV. 2012. The evidence for a role of B cells in multiple sclerosis. Neurology 78:823-832.
29. du Bois-Reymond E. 1843. Vorläufiger Abriss einer Untersuchung ueber den sogenannten Froschstrom und ueber die elektromotorischen Fische. Ann Phys 134:1-30.
30. Einstein O, Friedman-Levi Y, Grigoriadis N, Ben-Hur T. 2009. Transplanted neural precursors enhance host brain-derived myelin regeneration. J Neurosci 29:15694-15702.
31. Eisenbarth GS, Walsh FS, Nirenberg M. 1979. Monoclonal antibody to a plasma membrane antigen of neurons. Proc Natl Acad Sci U S A 76:4913-4917.
32. Eng LF, Chao FC, Gerstl B, Pratt D, Tavaststjerna MG. 1968. The maturation of human white matter myelin. Fractionation of the myelin membrane proteins. Biochemistry 7:4455-4465.
33. Fancy SP, Chan JR, Baranzini SE, Franklin RJ, Rowitch DH. 2011. Myelin regeneration: a recapitulation of development? Annu Rev Neurosci 34:21-43.
34. Fawcett JW, Asher RA. 1999. The glial scar and central nervous system repair. Brain Res Bull 49:377-391.
35. Felts PA, Baker TA, Smith KJ. 1997. Conduction in segmentally demyelinated mammalian central axons. J Neurosci 17:7267-7277.
36. Ferguson B, Matyszak MK, Esiri MM, Perry VH. 1997. Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399.
37. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G. 2013. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 6:CD008933.
38. Finkelstein G. 2003. M. du Bois-Reymond goes to Paris. Br J Hist Sci 36:261-300.
39. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. 2010. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162:1-11.
40. Fok-Seang J, Mathews GA, ffrench-Constant C, Trotter J, Fawcett JW. 1995. Migration of oligodendrocyte precursors on astrocytes and meningeal cells. Dev Biol 171:1-15.
41. Folch J, Lees M. 1951. Proteolipides, a new type of tissue lipoproteins; their isolation from brain. J Biol Chem 191:807-817.
42. Franklin RJ. 2002. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 3:705-714.
43. Friedman B, Hockfield S, Black JA, Woodruff KA, Waxman SG. 1989. In situ demonstration of mature oligodendrocytes and their processes: an immunocytochemical study with a new monoclonal antibody, rip. Glia 2:380-390.
44. Gudi V, Moharregh-Khiabani D, Skripuletz T, Koutsoudaki PN, Kotsiari A, Skuljec J, Trebst C, Stangel M. 2009. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res 1283:127-138.
45. Hanafy KA, Sloane JA. 2011. Regulation of remyelination in multiple sclerosis. FEBS Lett 585:3821-3828.
46. Harris VK, Faroqui R, Vyshkina T, Sadiq SA. 2012a. Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl Med 1:536-547.
47. Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA. 2012b. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci 313:167-177.
48. Hartline DK, Colman DR. 2007. Rapid conduction and the evolution of giant axons and myelinated fibers. Curr Biol 17:R29-R35.
49. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL. 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 19:578-587.
50. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-688.
51. Hayakawa K, Pham LD, Som AT, Lee BJ, Guo S, Lo EH, Arai K. 2011. Vascular endothelial growth factor regulates the migration of oligodendrocyte precursor cells. J Neurosci 31:10666-10670.
52. Hedayatpour A, Ragerdi I, Pasbakhsh P, Kafami L, Atlasi N, Pirhajati Mahabadi V, Ghasemi S, Reza M. 2013. Promotion of remyelination by adipose mesenchymal stem cell transplantation in a cuprizone model of multiple sclerosis. Cell J 15:142-151.
53. Henderson AP, Barnett MH, Parratt JD, Prineas JW. 2009. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 66:739-753.
54. Huxley AF, Stampfli R. 1949. Evidence for saltatory conduction in peripheral myelinated nerve fibres. J Physiol 108:315-339.
55. Iglesias-Rozas JR, Garrosa M. 2012. The discovery of oligodendroglia cells by Rio-Hortega: his original articles. 1921. Clin Neuropathol 31:437-439.
56. Jackman N, Ishii A, Bansal R. 2009. Oligodendrocyte development and myelin biogenesis: parsing out the roles of glycosphingolipids. Physiology 24:290-297.
57. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CC, Ben-Nun A. 1993. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 92:2602-2608.
58. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. 1999. Cortical lesions in multiple sclerosis. Brain 122:17-26.
59. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H. 2000. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157:267-276.
60. Kosturko LD, Maggipinto MJ, D'Sa C, Carson JH, Barbarese E. 2005. The microtubule-associated protein tumor overexpressed gene binds to the RNA trafficking protein heterogeneous nuclear ribonucleoprotein A2. Mol Biol Cell 16:1938-1947.
61. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Bruck W. 2008. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131:1749-1758.
62. Larochelle C, Alvarez JI, Prat A. 2011. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett 585:3770-3780.
63. Lebar R, Lubetzki C, Vincent C, Lombrail P, Boutry JM. 1986. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol 66:423-434.
64. Lee J, Gravel M, Zhang R, Thibault P, Braun PE. 2005. Process outgrowth in oligodendrocytes is mediated by CNP, a novel microtubule assembly myelin protein. J Cell Biol 170:661-673.
65. Lee S, Xu L, Shin Y, Gardner L, Hartzes A, Dohan FC, Raine C, Homayouni R, Levin MC. 2011. A potential link between autoimmunity and neurodegeneration in immune-mediated neurological disease. J Neuroimmunol 235:56-69.
66. Maki T, Liang AC, Miyamoto N, Lo EH, Arai K. 2013. Mechanisms of oligodendrocyte regeneration from ventricular-subventricular zone-derived progenitor cells in white matter diseases. Front Cell Neurosci 7:275.
67. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, Al-Hayani A, Davies SN, Rasband MN, Olsson T, Moldenhauer A, Velhin S, Hohlfeld R, Meinl E, Linington C. 2007. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 204:2363-2372.
68. 3H]concanavalin A binding. Biochem J 183:205-212.
69. Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, Wong WM, Wang L, Su H, Chu TH, Guo J, Zhang W, So KF, Pepinsky B, Shao Z, Graff C, Garber E, Jung V, Wu EX, Wu W. 2007. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13:1228-1233.
70. Mi S, Sandrock A, Miller RH. 2008. LINGO-1 and its role in CNS repair. Int J Biochem Cell Biol 40:1971-1978.
71. Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W, Zhang Y, Shields CB, Miklasz S, Shea D, Mason J, Franklin RJ, Ji B, Shao Z, Chedotal A, Bernard F, Roulois A, Xu J, Jung V, Pepinsky B. 2009. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 65:304-315.
72. Mi S, Pepinsky RB, Cadavid D. 2013. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs 27:493-503.
73. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. 2004. Axonal neuregulin-1 regulates myelin sheath thickness. Science 304:700-703.
74. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15-23.
75. Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, van Wijngaarden P, Wagers AJ, Williams A, Franklin RJ, ffrench-Constant C. 2013. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16:1211-1218.
76. Modell JG, Tandon R, Beresford TP. 1989. Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J Clin Psychopharmacol 9:347-351.
77. Monge M, Kadiiski D, Jacque CM, Zalc B. 1986. Oligodendroglial expression and deposition of four major myelin constituents in the myelin sheath during development. An in vivo study. Dev Neurosci 8:222-235.
78. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW. 1999. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19:8464-8475.
79. Oleszak EL, Chang JR, Friedman H, Katsetos CD, Platsoucas CD. 2004. Theiler's virus infection: a model for multiple sclerosis. Clin Microbiol Rev 17:174-207.
80. Oliver AR, Lyon GM, Ruddle NH. 2003. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol 171:462-468.
81. 2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci 22:14-24.
82. Pepinsky RB, Arndt JW, Quan C, Gao Y, Quintero-Monzon O, Lee X, Mi S. 2014. Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy. J Pharmacol Exp Ther 350:110-123.
83. Pirko I, Ciric B, Gamez J, Bieber AJ, Warrington AE, Johnson AJ, Hanson DP, Pease LR, Macura SI, Rodriguez M. 2004. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J 18:1577-1579.
84. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Del Carro U, Amadio S, Bergami A, Furlan R, Comi G, Vescovi AL, Martino G. 2003. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422:688-694.
85. Poltorak M, Sadoul R, Keilhauer G, Landa C, Fahrig T, Schachner M. 1987. Myelin-associated glycoprotein, a member of the L2/HNK-1 family of neural cell adhesion molecules, is involved in neuron-oligodendrocyte and oligodendrocyte-oligodendrocyte interaction. J Cell Biol 105:1893-1899.
86. Quarles RH, Everly JL, Brady RO. 1973. Evidence for the close association of a glycoprotein with myelin in rat brain. J Neurochem 21:1177-1191.
87. Radin NS, Akahori Y. 1961. Fatty acids of human brain cerebrosides. J Lipid Res 2:335-341.
88. Raff MC, Miller RH, Noble M. 1983. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303:390-396.
89. Rushton WA. 1951. A theory of the effects of fibre size in medullated nerve. J Physiol 115:101-122.
90. Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA. 2005. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 8:468-475.
91. Saher G, Quintes S, Nave KA. 2011. Cholesterol: a novel regulatory role in myelin formation. Neuroscientist 17:79-93.
92. Schwob VS, Clark HB, Agrawal D, Agrawal HC. 1985. Electron microscopic immunocytochemical localization of myelin proteolipid protein and myelin basic protein to oligodendrocytes in rat brain during myelination. J Neurochem 45:559-571.
93. Sherman DL, Brophy PJ. 2005. Mechanisms of axon ensheathment and myelin growth. Nat Rev Neurosci 6:683-690.
94. Silber E, Semra YK, Gregson NA, Sharief MK. 2002. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 58:1372-1381.
95. Simons M, Trajkovic K. 2006. Neuron-glia communication in the control of oligodendrocyte function and myelin biogenesis. J Cell Sci 119:4381-4389.
96. Slavin AJ, Johns TG, Orian JM, Bernard CC. 1997. Regulation of myelin oligodendrocyte glycoprotein in different species throughout development. Dev Neurosci 19:69-78.
97. Smith KJ, Lassmann H. 2002. The role of nitric oxide in multiple sclerosis. Lancet Neurol 1:232-241.
98. Smith KJ, Blakemore WF, McDonald WI. 1981. The restoration of conduction by central remyelination. Brain 104:383-404.
99. Smith KJ, Kapoor R, Felts PA. 1999. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9:69-92.
100. Sommer I, Schachner M. 1981. Monoclonal antibodies (O1 to O4) to oligodendrocyte cell surfaces: an immunocytological study in the central nervous system. Dev Biol 83:311-327.
101. Song J, Goetz BD, Baas PW, Duncan ID. 2001. Cytoskeletal reorganization during the formation of oligodendrocyte processes and branches. Mol Cell Neurosci 17:624-636.
102. Sriram S, Steiner I. 2005. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 58:939-945.
103. Stallcup WB. 1981. The NG2 antigen, a putative lineage marker: immunofluorescent localization in primary cultures of rat brain. Dev Biol 83:154-165.
104. Traka M, Arasi K, Avila RL, Podojil JR, Christakos A, Miller SD, Soliven B, Popko B. 2010. A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain 133:3017-3029.
105. Traugott U, Reinherz EL, Raine CS. 1983. Multiple sclerosis. Distribution of T cells, T-cell subsets, and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 4:201-221.
106. Virchow, Noad H, Völckel C. 1854. Notizen. J Prakt Chem 61:250-256.
107. Wang C, Liu F, Liu YY, Zhao CH, You Y, Wang L, Zhang J, Wei B, Ma T, Zhang Q, Zhang Y, Chen R, Song H, Yang Z. 2011. Identification and characterization of neuroblasts in the subventricular zone and rostral migratory stream of the adult human brain. Cell Res 21:1534-1550.
108. Warrington AE, Asakura K, Bieber AJ, Ciric B, Van Keulen V, Kaveri SV, Kyle RA, Pease LR, Rodriguez M. 2000. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A 97:6820-6825.
109. Waxman SG. 1977. Conduction in myelinated, unmyelinated, and demyelinated fibers. Arch Neurol 34:585-589.
110. Weiner HL. 2009. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65:239-248.
111. Wolswijk G. 1998. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 18:601-609.
112. Wu LM, Williams A, Delaney A, Sherman DL, Brophy PJ. 2012. Increasing internodal distance in myelinated nerves accelerates nerve conduction to a flat maximum. Curr Biol 22:1957-1961.
113. Young KM, Psachoulia K, Tripathi RB, Dunn SJ, Cossell L, Attwell D, Tohyama K, Richardson WD. 2013. Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling. Neuron 77:873-885.